Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

Mark G. Kris, Paul J. Hesketh, Jorn Herrstedt, Cynthia Rittenberg, Lawrence Einhorn, Steven Grunberg, Jim Koeller, Ian Olver, Sussanne Borjeson, Enzo Ballatori

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT3 antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT3) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.

Original languageEnglish (US)
Pages (from-to)85-96
Number of pages12
JournalSupportive Care in Cancer
Volume13
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Emetics
Antiemetics
aprepitant
Nausea
Vomiting
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Drug Therapy
Standard of Care
Intravenous Administration
Dexamethasone
Appointments and Schedules
Pharmaceutical Preparations
Therapeutics

Keywords

  • Aprepitant
  • Chemotherapy
  • Cisplatin
  • Dexamethasone
  • Serotonin antagonists

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. / Kris, Mark G.; Hesketh, Paul J.; Herrstedt, Jorn; Rittenberg, Cynthia; Einhorn, Lawrence; Grunberg, Steven; Koeller, Jim; Olver, Ian; Borjeson, Sussanne; Ballatori, Enzo.

In: Supportive Care in Cancer, Vol. 13, No. 2, 02.2005, p. 85-96.

Research output: Contribution to journalArticle

Kris, MG, Hesketh, PJ, Herrstedt, J, Rittenberg, C, Einhorn, L, Grunberg, S, Koeller, J, Olver, I, Borjeson, S & Ballatori, E 2005, 'Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy', Supportive Care in Cancer, vol. 13, no. 2, pp. 85-96. https://doi.org/10.1007/s00520-004-0699-x
Kris, Mark G. ; Hesketh, Paul J. ; Herrstedt, Jorn ; Rittenberg, Cynthia ; Einhorn, Lawrence ; Grunberg, Steven ; Koeller, Jim ; Olver, Ian ; Borjeson, Sussanne ; Ballatori, Enzo. / Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. In: Supportive Care in Cancer. 2005 ; Vol. 13, No. 2. pp. 85-96.
@article{3591758e297d4b05a5138c37e815d4d6,
title = "Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy",
abstract = "This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT3 antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT3) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.",
keywords = "Aprepitant, Chemotherapy, Cisplatin, Dexamethasone, Serotonin antagonists",
author = "Kris, {Mark G.} and Hesketh, {Paul J.} and Jorn Herrstedt and Cynthia Rittenberg and Lawrence Einhorn and Steven Grunberg and Jim Koeller and Ian Olver and Sussanne Borjeson and Enzo Ballatori",
year = "2005",
month = "2",
doi = "10.1007/s00520-004-0699-x",
language = "English (US)",
volume = "13",
pages = "85--96",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

AU - Kris, Mark G.

AU - Hesketh, Paul J.

AU - Herrstedt, Jorn

AU - Rittenberg, Cynthia

AU - Einhorn, Lawrence

AU - Grunberg, Steven

AU - Koeller, Jim

AU - Olver, Ian

AU - Borjeson, Sussanne

AU - Ballatori, Enzo

PY - 2005/2

Y1 - 2005/2

N2 - This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT3 antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT3) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.

AB - This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT3 antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT3) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.

KW - Aprepitant

KW - Chemotherapy

KW - Cisplatin

KW - Dexamethasone

KW - Serotonin antagonists

UR - http://www.scopus.com/inward/record.url?scp=20244390153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244390153&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0699-x

DO - 10.1007/s00520-004-0699-x

M3 - Article

C2 - 15565277

AN - SCOPUS:20244390153

VL - 13

SP - 85

EP - 96

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -